Elevance Health (ELV) Stock Trades Down, Here Is Why

Elevance Health (NYSE:EVH) shares declined 11.5% after the health insurer reported second-quarter adjusted earnings of $8.84 per share, missing consensus estimates, and significantly reduced its full-year 2025 profit guidance to approximately $30.00 from a previous range of $34.15-$34.85. Management attributed the downgrade to "elevated medical cost trends" in its Medicaid and Affordable Care Act plans, reflected in a higher benefit expense ratio of 88.9%. This development intensified existing sector-wide concerns regarding rising medical costs, which have recently impacted other major health insurers.

Analysis

Elevance Health (EVH) experienced a significant 11.5% share price decline following the release of its second-quarter results, which featured an earnings miss and a severe reduction in future profit guidance. The company reported adjusted EPS of $8.84, falling short of the $9.16 Wall Street consensus, and while revenue of $49.42 billion surpassed expectations, net income fell to $1.74 billion from $2.30 billion year-over-year. The primary driver of the market's strongly negative reaction was the substantial cut to the full-year 2025 profit outlook, with expected adjusted EPS now at approximately $30.00, a stark drop from the previous forecast of $34.15 to $34.85. Management directly attributed this downgrade to "elevated medical cost trends" within its Medicaid and ACA plans, a pressure quantified by the benefit expense ratio rising to 88.9%. This development confirms and exacerbates existing sector-wide concerns, particularly after peer Centene pulled its own guidance just 15 days prior for similar reasons, signaling a systemic issue of rising costs and margin pressure for health insurers rather than an isolated company problem.

Key Decisions for Investors

• Investors should recalibrate valuation models for Elevance Health to reflect the new, significantly lower long-term earnings base implied by the revised 2025 guidance of approximately $30.00 per share.
• Given that Elevance's announcement follows a similar warning from Centene, investors should treat the rising medical cost trend as a systemic risk for the entire managed care sector, warranting a cautious stance on peers as well.
• Closely monitor the benefit expense ratio in subsequent quarterly reports from Elevance and its competitors, as this metric will be a key indicator of whether margin pressures are stabilizing or worsening.
• Despite the stock trading 45.9% below its 52-week high, the fundamental justification for the decline is clear, so any consideration of buying on the dip must be weighed against the significant risk of continued earnings erosion.